Role of C5 inhibitors in neuromyelitis optica spectrum disorders with seropositive anti-aquaporin-4 antibody: A systematic review and meta-analysis
Article in Multiple Sclerosis and Related Disorders (March 2024)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Article in Frontiers in Neurology (January 2024)
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment
Article in Multiple Sclerosis and Related Disorders (August 2023)